The bill strengthens law-enforcement tools and evidence preservation to combat dangerous drug distribution but does so at the cost of expanded warrantless emergency disclosures, greater data-collection and reporting pressure on platforms, higher compliance costs, and risks of overreporting that may chill speech and burden providers.
Law enforcement and prosecutors gain faster access to account and message information to investigate and disrupt distribution of fentanyl, methamphetamine, and counterfeit prescription drugs.
Providers must preserve user data for investigations (up to 180 days), making evidence more available to build cases and potentially increasing convictions for serious drug crimes.
The Attorney General must publish annual statistics on reports and outcomes, increasing transparency about program use and provider compliance.
Everyday users' private communications and metadata could be disclosed to the government without a warrant in emergency situations, increasing privacy risks for ordinary Americans including children and youth.
Mandatory reporting and data-preservation obligations may pressure platforms to over-collect or share user data, chilling free expression and reducing trust in online services (especially affecting immigrants, children/youth).
Providers face significant criminal fines (up to $190,000 and higher for repeat violations) and civil penalties for reporting errors, raising compliance costs that could be passed on to customers or lead to reduced services.
Based on analysis of 3 sections of legislative text.
Requires electronic communication and remote computing providers to report and preserve records for federal investigations into fentanyl, meth, counterfeit drugs, and unlawful prescription-drug distribution.
Introduced July 17, 2025 by Mariannette Miller-Meeks · Last progress July 17, 2025
Requires electronic communication and remote computing service providers to report to the Attorney General when they learn of crimes involving fentanyl, methamphetamine, counterfeit drugs (including fake prescription pills), or unauthorized manufacture/distribution of prescription pain medicines or stimulants. Providers must preserve related records in emergencies, cooperate with investigations and lawful subpoenas within set timeframes, notify customers when records are disclosed (unless exigent circumstances), keep records, and face penalties for knowing failure to comply; the Attorney General must report annually to Congress. The bill also includes a standard severability clause.